Guirguis, Micheal
23  results:
Search for persons X
?
1

A Framework for Evaluating the Implementation of Biosimilar..:

Milgram, Lisa ; Wheeler, Sarah ; Adamic, Andrea...
https://www.cjhp-online.ca/index.php/cjhp/article/view/3272/4876.  , 2023
 
?
 
?
3

Prevalence of Venous Thromboembolism and Anticoagulant Use ..:

Schultz, Lynnea ; Bungard, Tammy J ; Mackay, Elizabeth..
https://www.cjhp-online.ca/index.php/cjhp/article/view/3209/4754.  , 2022
 
?
4

DOAC drug interactions management resource:

Chadha, Ayush ; Guirguis, Micheal ; Bungard, Tammy J
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647398/.  , 2022
 
?
6

Effect on Patients' Outcomes of a Change to Biosimilar Filg..:

Fenna, Jennifer ; Guirguis, Micheal ; Ibrahim, Caroline...
https://www.cjhp-online.ca/index.php/cjhp/article/view/3108/4394.  , 2021
 
?
9

Biosimilar Drugs and the Hospital Formulary: A Canadian Exp..:

Fenna, Jennifer ; Watkins, Kathy ; Guirguis, Micheal
https://www.cjhp-online.ca/index.php/cjhp/article/view/2885/3929.  , 2019
 
?
11

Venous Thromboembolism Prophylaxis on General Internal Medi..:

Mejilla, Allison ; Guirguis, Micheal ; Koshman, Sheri.
https://www.cjhp-online.ca/index.php/cjhp/article/view/1659/2553.  , 2017
 
?
14

Atherothrombotic events and clopidogrel therapy:

Guirguis, Micheal
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1780096.  , 2007
 
1-15